+
データを開く
-
基本情報
登録情報 | ![]() | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
タイトル | Structure of thermostabilised human NTCP in complex with Megabody 91 | |||||||||
![]() | ||||||||||
![]() |
| |||||||||
![]() | bile acid transporter / MEMBRANE PROTEIN | |||||||||
機能・相同性 | ![]() glucosidase complex / alpha,alpha-trehalase activity / trehalose catabolic process / bile acid:sodium symporter activity / glucosidase activity / bile acid transmembrane transporter activity / 加水分解酵素; 糖加水分解酵素; 配糖体結合加水分解酵素または糖加水分解酵素 / oligosaccharide catabolic process / bile acid and bile salt transport / Recycling of bile acids and salts ...glucosidase complex / alpha,alpha-trehalase activity / trehalose catabolic process / bile acid:sodium symporter activity / glucosidase activity / bile acid transmembrane transporter activity / 加水分解酵素; 糖加水分解酵素; 配糖体結合加水分解酵素または糖加水分解酵素 / oligosaccharide catabolic process / bile acid and bile salt transport / Recycling of bile acids and salts / response to nutrient levels / : / response to estrogen / cellular response to xenobiotic stimulus / virus receptor activity / basolateral plasma membrane / response to ethanol / DNA damage response / metal ion binding / plasma membrane 類似検索 - 分子機能 | |||||||||
生物種 | ![]() ![]() ![]() | |||||||||
手法 | 単粒子再構成法 / クライオ電子顕微鏡法 / 解像度: 3.3 Å | |||||||||
![]() | Goutam K / Reyes N | |||||||||
資金援助 | European Union, 1件
| |||||||||
![]() | ![]() タイトル: Structural basis of sodium-dependent bile salt uptake into the liver. 著者: Kapil Goutam / Francesco S Ielasi / Els Pardon / Jan Steyaert / Nicolas Reyes / ![]() ![]() 要旨: The liver takes up bile salts from blood to generate bile, enabling absorption of lipophilic nutrients and excretion of metabolites and drugs. Human Na-taurocholate co-transporting polypeptide (NTCP) ...The liver takes up bile salts from blood to generate bile, enabling absorption of lipophilic nutrients and excretion of metabolites and drugs. Human Na-taurocholate co-transporting polypeptide (NTCP) is the main bile salt uptake system in liver. NTCP is also the cellular entry receptor of human hepatitis B and D viruses (HBV/HDV), and has emerged as an important target for antiviral drugs. However, the molecular mechanisms underlying NTCP transport and viral receptor functions remain incompletely understood. Here we present cryo-electron microscopy structures of human NTCP in complexes with nanobodies, revealing key conformations of its transport cycle. NTCP undergoes a conformational transition opening a wide transmembrane pore that serves as the transport pathway for bile salts, and exposes key determinant residues for HBV/HDV binding to the outside of the cell. A nanobody that stabilizes pore closure and inward-facing states impairs recognition of the HBV/HDV receptor-binding domain preS1, demonstrating binding selectivity of the viruses for open-to-outside over inward-facing conformations of the NTCP transport cycle. These results provide molecular insights into NTCP 'gated-pore' transport and HBV/HDV receptor recognition mechanisms, and are expected to help with development of liver disease therapies targeting NTCP. | |||||||||
履歴 |
|
-
構造の表示
添付画像 |
---|
-
ダウンロードとリンク
-EMDBアーカイブ
マップデータ | ![]() | 79 MB | ![]() | |
---|---|---|---|---|
ヘッダ (付随情報) | ![]() ![]() | 18.5 KB 18.5 KB | 表示 表示 | ![]() |
画像 | ![]() | 102.7 KB | ||
Filedesc metadata | ![]() | 6.2 KB | ||
アーカイブディレクトリ | ![]() ![]() | HTTPS FTP |
-関連構造データ
関連構造データ | ![]() 7pqqMC ![]() 7pqgC M: このマップから作成された原子モデル C: 同じ文献を引用 ( |
---|---|
類似構造データ | 類似検索 - 機能・相同性 ![]() |
-
リンク
EMDBのページ | ![]() ![]() |
---|---|
「今月の分子」の関連する項目 |
-
マップ
ファイル | ![]() | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
投影像・断面図 | 画像のコントロール
画像は Spider により作成 | ||||||||||||||||||||||||||||||||||||
ボクセルのサイズ | X=Y=Z: 1.008 Å | ||||||||||||||||||||||||||||||||||||
密度 |
| ||||||||||||||||||||||||||||||||||||
対称性 | 空間群: 1 | ||||||||||||||||||||||||||||||||||||
詳細 | EMDB XML:
|
-添付データ
-
試料の構成要素
-全体 : human NTCP complexed with Megabody 91
全体 | 名称: human NTCP complexed with Megabody 91 |
---|---|
要素 |
|
-超分子 #1: human NTCP complexed with Megabody 91
超分子 | 名称: human NTCP complexed with Megabody 91 / タイプ: complex / ID: 1 / 親要素: 0 / 含まれる分子: all |
---|---|
由来(天然) | 生物種: ![]() |
-分子 #1: Sodium/bile acid cotransporter
分子 | 名称: Sodium/bile acid cotransporter / タイプ: protein_or_peptide / ID: 1 / コピー数: 1 / 光学異性体: LEVO |
---|---|
由来(天然) | 生物種: ![]() |
分子量 | 理論値: 36.652391 KDa |
組換発現 | 生物種: ![]() |
配列 | 文字列: MAHTASAPFT FTLPPNFGKR PTDLALSVIL VVMLFIIMLS LGCTMEFSKI KAHLWKPKGL AIALVAQYGI MPLTAFVLGK VFRLNNIEA LAILICGCSP GGNLSNIFSL AMKGDMNLSI VMTTCSTFLA LGMMPLLLYI YSRGIYDGDL KDKVPYKGIV I SLVLVLIP ...文字列: MAHTASAPFT FTLPPNFGKR PTDLALSVIL VVMLFIIMLS LGCTMEFSKI KAHLWKPKGL AIALVAQYGI MPLTAFVLGK VFRLNNIEA LAILICGCSP GGNLSNIFSL AMKGDMNLSI VMTTCSTFLA LGMMPLLLYI YSRGIYDGDL KDKVPYKGIV I SLVLVLIP CTIGIVLKSK RPQYMRYVIK GGMIIILLCS VAVTVLSAIN VGKSIMFAMT PHLIATSSLM PFIGFLLGYV LS ALFCLNG RCRRTVSMET GCQNVQLCST ILNVAFPPEV IGPLFFFPLL YMIFQLGEGL LLIAIFWCYE KFKTPKDKTK MIY TAATTE ELEVLFQ UniProtKB: Hepatic sodium/bile acid cotransporter |
-分子 #2: Anti-RON nanobody,Megabody 91,Glucosidase YgjK
分子 | 名称: Anti-RON nanobody,Megabody 91,Glucosidase YgjK / タイプ: protein_or_peptide / ID: 2 詳細: The megabody scaffold is excluded from the structure during refinement and model building. The build model corresponds to residues 2-12 and 788-895 belonging to nanobody part only. The ...詳細: The megabody scaffold is excluded from the structure during refinement and model building. The build model corresponds to residues 2-12 and 788-895 belonging to nanobody part only. The alignment software here is misaligning N-terminal part so I have just put build sequence in the sample sequence box. Here is the full sequence: QVQLVESGGGLV KEETQSGLNNYARVVEKGQYDSLEIPAQVAASWESGRDDAAVFGFIDKEQLDKYVANGGKRSDWTVKFAENRSQDGTLLGYSLLQESVDQASYMYSDNHYLAEMATILGKPEEAKRYRQLAQQLADYINTCMFDPTTQFYYDVRIEDKPLANGCAGKPIVERGKGPEGWSPLFNGAATQANADAVVKVMLDPKEFNTFVPLGTAALTNPAFGADIYWRGRVWVDQFWFGLKGMERYGYRDDALKLADTFFRHAKGLTADGPIQENYNPLTGAQQGAPNFSWSAAHLYMLYNDFFRKQASGGGSGGGGSGGGGSGNADNYKNVINRTGAPQYMKDYDYDDHQRFNPFFDLGAWHGHLLPDGPNTMGGFPGVALLTEEYINFMASNFDRLTVWQDGKKVDFTLEAYSIPGALVQKLTAKDVQVEMTLRFATPRTSLLETKITSNKPLDLVWDGELLEKLEAKEGKPLSDKTIAGEYPDYQRKISATRDGLKVTFGKVRATWDLLTSGESEYQVHKSLPVQTEINGNRFTSKAHINGSTTLYTTYSHLLTAQEVSKEQMQIRDILARPAFYLTASQQRWEEYLKKGLTNPDATPEQTRVAVKAIETLNGNWRSPGGAVKFNTVTPSVTGRWFSGNQTWPWDTWKQAFAMAHFNPDIAKENIRAVFSWQIQPGDSVRPQDVGFVPDLIAWNLSPERGGDGGNWNERNTKPSLAAWSVMEVYNVTQDKTWVAEMYPKLVAYHDWWLRNRDHNGNGVPEYGATRDKAHNTESGEMLFTVKK SLRLSCAASTNLRSYAMAWFRQAPGKEREFVSFINWNYGNTRYA DSVKGRFTISRDNAKITVYLQMNSLKPEDTAVYYCAAATIGRLAGIDSTTLYDYWGQGTQ VTVSSHHHHHHEPEA,The megabody scaffold is excluded from the structure during refinement and model building. The build model corresponds to residues 2-12 and 788-895 belonging to nanobody part only. The alignment software here is misaligning N-terminal part so I have just put build sequence in the sample sequence box. Here is the full sequence: QVQLVESGGGLV KEETQSGLNNYARVVEKGQYDSLEIPAQVAASWESGRDDAAVFGFIDKEQLDKYVANGGKRSDWTVKFAENRSQDGTLLGYSLLQESVDQASYMYSDNHYLAEMATILGKPEEAKRYRQLAQQLADYINTCMFDPTTQFYYDVRIEDKPLANGCAGKPIVERGKGPEGWSPLFNGAATQANADAVVKVMLDPKEFNTFVPLGTAALTNPAFGADIYWRGRVWVDQFWFGLKGMERYGYRDDALKLADTFFRHAKGLTADGPIQENYNPLTGAQQGAPNFSWSAAHLYMLYNDFFRKQASGGGSGGGGSGGGGSGNADNYKNVINRTGAPQYMKDYDYDDHQRFNPFFDLGAWHGHLLPDGPNTMGGFPGVALLTEEYINFMASNFDRLTVWQDGKKVDFTLEAYSIPGALVQKLTAKDVQVEMTLRFATPRTSLLETKITSNKPLDLVWDGELLEKLEAKEGKPLSDKTIAGEYPDYQRKISATRDGLKVTFGKVRATWDLLTSGESEYQVHKSLPVQTEINGNRFTSKAHINGSTTLYTTYSHLLTAQEVSKEQMQIRDILARPAFYLTASQQRWEEYLKKGLTNPDATPEQTRVAVKAIETLNGNWRSPGGAVKFNTVTPSVTGRWFSGNQTWPWDTWKQAFAMAHFNPDIAKENIRAVFSWQIQPGDSVRPQDVGFVPDLIAWNLSPERGGDGGNWNERNTKPSLAAWSVMEVYNVTQDKTWVAEMYPKLVAYHDWWLRNRDHNGNGVPEYGATRDKAHNTESGEMLFTVKK SLRLSCAASTNLRSYAMAWFRQAPGKEREFVSFINWNYGNTRYA DSVKGRFTISRDNAKITVYLQMNSLKPEDTAVYYCAAATIGRLAGIDSTTLYDYWGQGTQ VTVSSHHHHHHEPEA,The megabody scaffold is excluded from the structure during refinement and model building. The build model corresponds to residues 2-12 and 788-895 belonging to nanobody part only. The alignment software here is misaligning N-terminal part so I have just put build sequence in the sample sequence box. Here is the full sequence: QVQLVESGGGLV KEETQSGLNNYARVVEKGQYDSLEIPAQVAASWESGRDDAAVFGFIDKEQLDKYVANGGKRSDWTVKFAENRSQDGTLLGYSLLQESVDQASYMYSDNHYLAEMATILGKPEEAKRYRQLAQQLADYINTCMFDPTTQFYYDVRIEDKPLANGCAGKPIVERGKGPEGWSPLFNGAATQANADAVVKVMLDPKEFNTFVPLGTAALTNPAFGADIYWRGRVWVDQFWFGLKGMERYGYRDDALKLADTFFRHAKGLTADGPIQENYNPLTGAQQGAPNFSWSAAHLYMLYNDFFRKQASGGGSGGGGSGGGGSGNADNYKNVINRTGAPQYMKDYDYDDHQRFNPFFDLGAWHGHLLPDGPNTMGGFPGVALLTEEYINFMASNFDRLTVWQDGKKVDFTLEAYSIPGALVQKLTAKDVQVEMTLRFATPRTSLLETKITSNKPLDLVWDGELLEKLEAKEGKPLSDKTIAGEYPDYQRKISATRDGLKVTFGKVRATWDLLTSGESEYQVHKSLPVQTEINGNRFTSKAHINGSTTLYTTYSHLLTAQEVSKEQMQIRDILARPAFYLTASQQRWEEYLKKGLTNPDATPEQTRVAVKAIETLNGNWRSPGGAVKFNTVTPSVTGRWFSGNQTWPWDTWKQAFAMAHFNPDIAKENIRAVFSWQIQPGDSVRPQDVGFVPDLIAWNLSPERGGDGGNWNERNTKPSLAAWSVMEVYNVTQDKTWVAEMYPKLVAYHDWWLRNRDHNGNGVPEYGATRDKAHNTESGEMLFTVKK SLRLSCAASTNLRSYAMAWFRQAPGKEREFVSFINWNYGNTRYA DSVKGRFTISRDNAKITVYLQMNSLKPEDTAVYYCAAATIGRLAGIDSTTLYDYWGQGTQ VTVSSHHHHHHEPEA,The megabody scaffold is excluded from the structure during refinement and model building. The build model corresponds to residues 2-12 and 788-895 belonging to nanobody part only. The alignment software here is misaligning N-terminal part so I have just put build sequence in the sample sequence box. Here is the full sequence: QVQLVESGGGLV KEETQSGLNNYARVVEKGQYDSLEIPAQVAASWESGRDDAAVFGFIDKEQLDKYVANGGKRSDWTVKFAENRSQDGTLLGYSLLQESVDQASYMYSDNHYLAEMATILGKPEEAKRYRQLAQQLADYINTCMFDPTTQFYYDVRIEDKPLANGCAGKPIVERGKGPEGWSPLFNGAATQANADAVVKVMLDPKEFNTFVPLGTAALTNPAFGADIYWRGRVWVDQFWFGLKGMERYGYRDDALKLADTFFRHAKGLTADGPIQENYNPLTGAQQGAPNFSWSAAHLYMLYNDFFRKQASGGGSGGGGSGGGGSGNADNYKNVINRTGAPQYMKDYDYDDHQRFNPFFDLGAWHGHLLPDGPNTMGGFPGVALLTEEYINFMASNFDRLTVWQDGKKVDFTLEAYSIPGALVQKLTAKDVQVEMTLRFATPRTSLLETKITSNKPLDLVWDGELLEKLEAKEGKPLSDKTIAGEYPDYQRKISATRDGLKVTFGKVRATWDLLTSGESEYQVHKSLPVQTEINGNRFTSKAHINGSTTLYTTYSHLLTAQEVSKEQMQIRDILARPAFYLTASQQRWEEYLKKGLTNPDATPEQTRVAVKAIETLNGNWRSPGGAVKFNTVTPSVTGRWFSGNQTWPWDTWKQAFAMAHFNPDIAKENIRAVFSWQIQPGDSVRPQDVGFVPDLIAWNLSPERGGDGGNWNERNTKPSLAAWSVMEVYNVTQDKTWVAEMYPKLVAYHDWWLRNRDHNGNGVPEYGATRDKAHNTESGEMLFTVKK SLRLSCAASTNLRSYAMAWFRQAPGKEREFVSFINWNYGNTRYA DSVKGRFTISRDNAKITVYLQMNSLKPEDTAVYYCAAATIGRLAGIDSTTLYDYWGQGTQ VTVSSHHHHHHEPEA,The megabody scaffold is excluded from the structure during refinement and model building. The build model corresponds to residues 2-12 and 788-895 belonging to nanobody part only. The alignment software here is misaligning N-terminal part so I have just put build sequence in the sample sequence box. Here is the full sequence: QVQLVESGGGLV KEETQSGLNNYARVVEKGQYDSLEIPAQVAASWESGRDDAAVFGFIDKEQLDKYVANGGKRSDWTVKFAENRSQDGTLLGYSLLQESVDQASYMYSDNHYLAEMATILGKPEEAKRYRQLAQQLADYINTCMFDPTTQFYYDVRIEDKPLANGCAGKPIVERGKGPEGWSPLFNGAATQANADAVVKVMLDPKEFNTFVPLGTAALTNPAFGADIYWRGRVWVDQFWFGLKGMERYGYRDDALKLADTFFRHAKGLTADGPIQENYNPLTGAQQGAPNFSWSAAHLYMLYNDFFRKQASGGGSGGGGSGGGGSGNADNYKNVINRTGAPQYMKDYDYDDHQRFNPFFDLGAWHGHLLPDGPNTMGGFPGVALLTEEYINFMASNFDRLTVWQDGKKVDFTLEAYSIPGALVQKLTAKDVQVEMTLRFATPRTSLLETKITSNKPLDLVWDGELLEKLEAKEGKPLSDKTIAGEYPDYQRKISATRDGLKVTFGKVRATWDLLTSGESEYQVHKSLPVQTEINGNRFTSKAHINGSTTLYTTYSHLLTAQEVSKEQMQIRDILARPAFYLTASQQRWEEYLKKGLTNPDATPEQTRVAVKAIETLNGNWRSPGGAVKFNTVTPSVTGRWFSGNQTWPWDTWKQAFAMAHFNPDIAKENIRAVFSWQIQPGDSVRPQDVGFVPDLIAWNLSPERGGDGGNWNERNTKPSLAAWSVMEVYNVTQDKTWVAEMYPKLVAYHDWWLRNRDHNGNGVPEYGATRDKAHNTESGEMLFTVKK SLRLSCAASTNLRSYAMAWFRQAPGKEREFVSFINWNYGNTRYA DSVKGRFTISRDNAKITVYLQMNSLKPEDTAVYYCAAATIGRLAGIDSTTLYDYWGQGTQ VTVSSHHHHHHEPEA,The megabody scaffold is excluded from the structure during refinement and model building. The build model corresponds to residues 2-12 and 788-895 belonging to nanobody part only. The alignment software here is misaligning N-terminal part so I have just put build sequence in the sample sequence box. Here is the full sequence: QVQLVESGGGLV KEETQSGLNNYARVVEKGQYDSLEIPAQVAASWESGRDDAAVFGFIDKEQLDKYVANGGKRSDWTVKFAENRSQDGTLLGYSLLQESVDQASYMYSDNHYLAEMATILGKPEEAKRYRQLAQQLADYINTCMFDPTTQFYYDVRIEDKPLANGCAGKPIVERGKGPEGWSPLFNGAATQANADAVVKVMLDPKEFNTFVPLGTAALTNPAFGADIYWRGRVWVDQFWFGLKGMERYGYRDDALKLADTFFRHAKGLTADGPIQENYNPLTGAQQGAPNFSWSAAHLYMLYNDFFRKQASGGGSGGGGSGGGGSGNADNYKNVINRTGAPQYMKDYDYDDHQRFNPFFDLGAWHGHLLPDGPNTMGGFPGVALLTEEYINFMASNFDRLTVWQDGKKVDFTLEAYSIPGALVQKLTAKDVQVEMTLRFATPRTSLLETKITSNKPLDLVWDGELLEKLEAKEGKPLSDKTIAGEYPDYQRKISATRDGLKVTFGKVRATWDLLTSGESEYQVHKSLPVQTEINGNRFTSKAHINGSTTLYTTYSHLLTAQEVSKEQMQIRDILARPAFYLTASQQRWEEYLKKGLTNPDATPEQTRVAVKAIETLNGNWRSPGGAVKFNTVTPSVTGRWFSGNQTWPWDTWKQAFAMAHFNPDIAKENIRAVFSWQIQPGDSVRPQDVGFVPDLIAWNLSPERGGDGGNWNERNTKPSLAAWSVMEVYNVTQDKTWVAEMYPKLVAYHDWWLRNRDHNGNGVPEYGATRDKAHNTESGEMLFTVKK SLRLSCAASTNLRSYAMAWFRQAPGKEREFVSFINWNYGNTRYA DSVKGRFTISRDNAKITVYLQMNSLKPEDTAVYYCAAATIGRLAGIDSTTLYDYWGQGTQ VTVSSHHHHHHEPEA コピー数: 1 / 光学異性体: LEVO EC番号: 加水分解酵素; 糖加水分解酵素; 配糖体結合加水分解酵素または糖加水分解酵素 |
---|---|
由来(天然) | 生物種: ![]() ![]() |
分子量 | 理論値: 101.583031 KDa |
組換発現 | 生物種: ![]() ![]() |
配列 | 文字列: QVQLVESGGG LVKEETQSGL NNYARVVEKG QYDSLEIPAQ VAASWESGRD DAAVFGFIDK EQLDKYVANG GKRSDWTVKF AENRSQDGT LLGYSLLQES VDQASYMYSD NHYLAEMATI LGKPEEAKRY RQLAQQLADY INTCMFDPTT QFYYDVRIED K PLANGCAG ...文字列: QVQLVESGGG LVKEETQSGL NNYARVVEKG QYDSLEIPAQ VAASWESGRD DAAVFGFIDK EQLDKYVANG GKRSDWTVKF AENRSQDGT LLGYSLLQES VDQASYMYSD NHYLAEMATI LGKPEEAKRY RQLAQQLADY INTCMFDPTT QFYYDVRIED K PLANGCAG KPIVERGKGP EGWSPLFNGA ATQANADAVV KVMLDPKEFN TFVPLGTAAL TNPAFGADIY WRGRVWVDQF WF GLKGMER YGYRDDALKL ADTFFRHAKG LTADGPIQEN YNPLTGAQQG APNFSWSAAH LYMLYNDFFR KQASGGGSGG GGS GGGGSG NADNYKNVIN RTGAPQYMKD YDYDDHQRFN PFFDLGAWHG HLLPDGPNTM GGFPGVALLT EEYINFMASN FDRL TVWQD GKKVDFTLEA YSIPGALVQK LTAKDVQVEM TLRFATPRTS LLETKITSNK PLDLVWDGEL LEKLEAKEGK PLSDK TIAG EYPDYQRKIS ATRDGLKVTF GKVRATWDLL TSGESEYQVH KSLPVQTEIN GNRFTSKAHI NGSTTLYTTY SHLLTA QEV SKEQMQIRDI LARPAFYLTA SQQRWEEYLK KGLTNPDATP EQTRVAVKAI ETLNGNWRSP GGAVKFNTVT PSVTGRW FS GNQTWPWDTW KQAFAMAHFN PDIAKENIRA VFSWQIQPGD SVRPQDVGFV PDLIAWNLSP ERGGDGGNWN ERNTKPSL A AWSVMEVYNV TQDKTWVAEM YPKLVAYHDW WLRNRDHNGN GVPEYGATRD KAHNTESGEM LFTVKKSLRL SCAASTNLR SYAMAWFRQA PGKEREFVSF INWNYGNTRY ADSVKGRFTI SRDNAKITVY LQMNSLKPED TAVYYCAAAT IGRLAGIDST TLYDYWGQG TQVTVSSHHH HHHEPEA UniProtKB: Glucosidase YgjK |
-実験情報
-構造解析
手法 | クライオ電子顕微鏡法 |
---|---|
![]() | 単粒子再構成法 |
試料の集合状態 | particle |
-
試料調製
緩衝液 | pH: 7.4 |
---|---|
凍結 | 凍結剤: ETHANE |
-
電子顕微鏡法
顕微鏡 | FEI TITAN KRIOS |
---|---|
撮影 | フィルム・検出器のモデル: GATAN K3 BIOQUANTUM (6k x 4k) 平均電子線量: 56.5 e/Å2 |
電子線 | 加速電圧: 300 kV / 電子線源: ![]() |
電子光学系 | 照射モード: FLOOD BEAM / 撮影モード: BRIGHT FIELD |
実験機器 | ![]() モデル: Titan Krios / 画像提供: FEI Company |
-
画像解析
初期モデル | モデルのタイプ: INSILICO MODEL In silico モデル: The initial model for Nanobody was created using I-TASSER server. 詳細: Transporter was modelled de novo. |
---|---|
最終 再構成 | 解像度のタイプ: BY AUTHOR / 解像度: 3.3 Å / 解像度の算出法: FSC 0.143 CUT-OFF / 使用した粒子像数: 184768 |
初期 角度割当 | タイプ: MAXIMUM LIKELIHOOD |
最終 角度割当 | タイプ: MAXIMUM LIKELIHOOD |